Amgen Announces Results of the ``145 Study''.

M2 PRESSWIRE-19 April 2007-Afternoon Movers: Amgen Announces Results of the ``145 Study''(C)1994-2007 M2 COMMUNICATIONS LTD

RDATE:19042007

Market Gainer is quickly emerging as the one stop shop for international small-cap investors looking to stay a step ahead of the markets. Activity on the NASDAQ market has brought this company to the attention of our research team. Amgen (NASDAQ: AMGN), is responding to the attention of investors. Our goal is to create a community of international investors who consistently and effectively capitalize on the enormous gains the small-cap Canadian and American exchanges offer.

Amgen (NASDAQ: AMGN announced the results of the "145 study", a randomized, double-blind, placebo-controlled, multicenter Phase 3 study of Aranesp (darbepoetin alfa) in 600 previously untreated patients with extensive-stage small-cell lung cancer (SCLC) receiving platinum-containing chemotherapy. The study demonstrated no statistically significant difference in risk of death (overall survival Aranesp compared to placebo Hazard Ratio (HR): 0.93, 95 CI: 0.78 to 1.11) or investigator determined progression-free survival (HR: 1.02, 95 CI: 0.86 to 1.21).

The study demonstrated a significant change in hemoglobin concentration from baseline in favor of Aranesp (a co-primary endpoint). Aranesp-treated patients also experienced a significantly lower risk of blood transfusions (HR: 0.40, 95 CI: 0.29 to 0.55). The overall safety profile, including thromboembolic events, was consistent with that described in the U.S. label.

"The 145 study is a component of Amgen's ongoing pharmacovigilance program designed to evaluate the effect of Aranesp on long-term survival in patients with chemotherapy-induced anemia. This study had higher…